Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured...
FDA Drug Recall #D-0775-2021 — Class II — July 29, 2021
Recall Summary
| Recall Number | D-0775-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 29, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Teva Pharmaceuticals USA |
| Location | Parsippany, NJ |
| Product Type | Drugs |
| Quantity | 4,587 bottles |
Product Description
Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc. Fort Lauderdale, FL 33314, NDC 70199-014-01
Reason for Recall
CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.
Distribution Pattern
Product was distributed nationwide.
Lot / Code Information
1408822A, exp. date 08/2023 (labeler - Casper)
Other Recalls from Teva Pharmaceuticals USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0461-2022 | Class II | Doxylamine Succinate and Pyridoxine Hydrochlori... | Jan 18, 2022 |
| D-0520-2022 | Class II | Tretinoin Capsules, 10 mg, 100 count bottle, Rx... | Jan 10, 2022 |
| D-0522-2022 | Class III | Mimvey (estradiol and norethindrone acetate tab... | Jan 7, 2022 |
| D-0521-2022 | Class III | Mimvey (estradiol and norethindrone acetate tab... | Jan 7, 2022 |
| D-0370-2022 | Class II | MethylPREDNISolone Acetate Injectable Suspensio... | Dec 31, 2021 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.